RTRX

Insider ownership of Retrophin, Inc.

1.55%
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Insider ownership of companies in the Health Care sector on NASDAQ compared to Retrophin, Inc.

Retrophin, Inc. logo

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

  • Retrophin, Inc., 3721 Valley Centre Drive, San Diego 92130, United States
  • retrophin.com
  • 760-260-8600